Literature DB >> 15308685

Developmental changes in CSF hypocretin-1 (orexin-A) levels in normal and genetically narcoleptic Doberman pinschers.

Joshi John1, Ming-Fung Wu, Nigel T Maidment, Hoa A Lam, Lisa N Boehmer, Melanie Patton, Jerome M Siegel.   

Abstract

Loss of hypocretin cells or mutation of hypocretin receptors causes narcolepsy. In canine genetic narcolepsy, produced by a mutation of the Hcrtr2 gene, symptoms develop postnatally with symptom onset at 4 weeks of age and maximal symptom severity by 10-32 weeks of age. Canine narcolepsy can readily be quantified. The large size of the dog cerebrospinal fluid (CSF) cerebellomedullary cistern allows the withdrawal of sufficient volumes of CSF for accurate assay of hypocretin levels, as early as postnatal day 4. We have taken advantage of these features to determine the relation of CSF hypocretin levels to symptom onset and compare hypocretin levels in narcoleptic and normal dogs. We find that by 4 days after birth, Hcrtr2 mutants have significantly higher levels of Hcrt than normal age- and breed-matched dogs. These levels were also significantly higher than those in adult narcoleptic and normal dogs. A reduction followed by an increase in Hcrt levels coincides with symptom onset and increase in the narcoleptics. The Hcrtr2 mutation alters the normal developmental course of hypocretin levels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308685      PMCID: PMC1665256          DOI: 10.1113/jphysiol.2004.070573

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  24 in total

1.  The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene.

Authors:  L Lin; J Faraco; R Li; H Kadotani; W Rogers; X Lin; X Qiu; P J de Jong; S Nishino; E Mignot
Journal:  Cell       Date:  1999-08-06       Impact factor: 41.582

Review 2.  Pharmacological aspects of human and canine narcolepsy.

Authors:  S Nishino; E Mignot
Journal:  Prog Neurobiol       Date:  1997-05       Impact factor: 11.685

3.  Hypocretin (orexin) deficiency in human narcolepsy.

Authors:  S Nishino; B Ripley; S Overeem; G J Lammers; E Mignot
Journal:  Lancet       Date:  2000-01-01       Impact factor: 79.321

Review 4.  Diagnostic aspects of narcolepsy.

Authors:  M S Aldrich
Journal:  Neurology       Date:  1998-02       Impact factor: 9.910

5.  Orexin A but not orexin B rapidly enters brain from blood by simple diffusion.

Authors:  A J Kastin; V Akerstrom
Journal:  J Pharmacol Exp Ther       Date:  1999-04       Impact factor: 4.030

6.  Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.

Authors:  T Sakurai; A Amemiya; M Ishii; I Matsuzaki; R M Chemelli; H Tanaka; S C Williams; J A Richardson; G P Kozlowski; S Wilson; J R Arch; R E Buckingham; A C Haynes; S A Carr; R S Annan; D E McNulty; W S Liu; J A Terrett; N A Elshourbagy; D J Bergsma; M Yanagisawa
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

7.  Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.

Authors:  R M Chemelli; J T Willie; C M Sinton; J K Elmquist; T Scammell; C Lee; J A Richardson; S C Williams; Y Xiong; Y Kisanuki; T E Fitch; M Nakazato; R E Hammer; C B Saper; M Yanagisawa
Journal:  Cell       Date:  1999-08-20       Impact factor: 41.582

8.  Development of cataplexy in genetically narcoleptic Dobermans.

Authors:  J Riehl; S Nishino; R Cederberg; W C Dement; E Mignot
Journal:  Exp Neurol       Date:  1998-08       Impact factor: 5.330

9.  Neuronal degeneration in canine narcolepsy.

Authors:  J M Siegel; R Nienhuis; S Gulyani; S Ouyang; M F Wu; E Mignot; R C Switzer; G McMurry; M Cornford
Journal:  J Neurosci       Date:  1999-01-01       Impact factor: 6.167

10.  Treatment with immunosuppressive and anti-inflammatory agents delays onset of canine genetic narcolepsy and reduces symptom severity.

Authors:  L N Boehmer; M-F Wu; J John; J M Siegel
Journal:  Exp Neurol       Date:  2004-08       Impact factor: 5.330

View more
  7 in total

Review 1.  Man's best friend becomes biology's best in show: genome analyses in the domestic dog.

Authors:  Heidi G Parker; Abigail L Shearin; Elaine A Ostrander
Journal:  Annu Rev Genet       Date:  2010       Impact factor: 16.830

2.  CSF levels of hypocretin-1 (orexin-A) peak during early infancy in humans.

Authors:  Adi Aran; Irina Shors; Ling Lin; Emmanuel Mignot; Michael S Schimmel
Journal:  Sleep       Date:  2012-02-01       Impact factor: 5.849

3.  Role of the hypocretin (orexin) receptor 2 (Hcrt-r2) in the regulation of hypocretin level and cataplexy.

Authors:  Ming-Fung Wu; Robert Nienhuis; Nigel Maidment; Hoa A Lam; Jerome M Siegel
Journal:  J Neurosci       Date:  2011-04-27       Impact factor: 6.167

4.  Developmental divergence of sleep-wake patterns in orexin knockout and wild-type mice.

Authors:  Mark S Blumberg; Cassandra M Coleman; Eric D Johnson; Cynthia Shaw
Journal:  Eur J Neurosci       Date:  2007-01       Impact factor: 3.386

Review 5.  The anatomical, cellular and synaptic basis of motor atonia during rapid eye movement sleep.

Authors:  Elda Arrigoni; Michael C Chen; Patrick M Fuller
Journal:  J Physiol       Date:  2016-07-03       Impact factor: 5.182

6.  Animal models of narcolepsy.

Authors:  Lichao Chen; Ritchie E Brown; James T McKenna; Robert W McCarley
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-08       Impact factor: 4.388

7.  Gender differences between hypocretin/orexin knockout and wild type mice: age, body weight, body composition, metabolic markers, leptin and insulin resistance.

Authors:  Lalini Ramanathan; Jerome M Siegel
Journal:  J Neurochem       Date:  2014-08-21       Impact factor: 5.372

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.